Iterum Therapeutics Plc (ITRM) Tops Q1 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Iterum Therapeutics Reports First Quarter 2020 Financial Results
May 14, 2020 6:45 AM EDT--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 --
-- Raised $51.6 million through a private placement with new and existing investors --
DUBLIN, Ireland and CHICAGO, May 14, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2020.
"During this challenging... More
